Inmed Pharmaceuticals Stock Market Value
| INM Stock | USD 5.26 0.11 2.14% |
| Symbol | InMed |
InMed Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
InMed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to InMed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of InMed Pharmaceuticals.
| 11/15/2024 |
| 12/15/2024 |
If you would invest 0.00 in InMed Pharmaceuticals on November 15, 2024 and sell it all today you would earn a total of 0.00 from holding InMed Pharmaceuticals or generate 0.0% return on investment in InMed Pharmaceuticals over 30 days. InMed Pharmaceuticals is related to or competes with Quoin Pharmaceuticals, Allarity Therapeutics, Virax Biolabs, Biodexa Pharmaceticals, LMF Acquisition, ZyVersa Therapeutics, and Sonnet Biotherapeutics. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products More
InMed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure InMed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess InMed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.82 | |||
| Information Ratio | 0.0043 | |||
| Maximum Drawdown | 39.14 | |||
| Value At Risk | (9.22) | |||
| Potential Upside | 10.0 |
InMed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for InMed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as InMed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use InMed Pharmaceuticals historical prices to predict the future InMed Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0226 | |||
| Jensen Alpha | 0.1627 | |||
| Total Risk Alpha | (0.73) | |||
| Sortino Ratio | 0.0043 | |||
| Treynor Ratio | (0.25) |
InMed Pharmaceuticals Backtested Returns
InMed Pharmaceuticals appears to be very risky, given 3 months investment horizon. InMed Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.043, which attests that the entity had a 0.043% return per unit of volatility over the last 3 months. We have found thirty technical indicators for InMed Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please utilize InMed Pharmaceuticals' market risk adjusted performance of (0.24), and Risk Adjusted Performance of 0.0226 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, InMed Pharmaceuticals holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of -0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning InMed Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, InMed Pharmaceuticals is likely to outperform the market. Please check InMed Pharmaceuticals' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether InMed Pharmaceuticals' current trending patterns will revert.
Auto-correlation | 0.38 |
Below average predictability
InMed Pharmaceuticals has below average predictability. Overlapping area represents the amount of predictability between InMed Pharmaceuticals time series from 15th of November 2024 to 30th of November 2024 and 30th of November 2024 to 15th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of InMed Pharmaceuticals price movement. The serial correlation of 0.38 indicates that just about 38.0% of current InMed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
InMed Pharmaceuticals lagged returns against current returns
Autocorrelation, which is InMed Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting InMed Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of InMed Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that InMed Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
InMed Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If InMed Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if InMed Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in InMed Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
InMed Pharmaceuticals Lagged Returns
When evaluating InMed Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of InMed Pharmaceuticals stock have on its future price. InMed Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, InMed Pharmaceuticals autocorrelation shows the relationship between InMed Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in InMed Pharmaceuticals.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out InMed Pharmaceuticals Correlation, InMed Pharmaceuticals Volatility and InMed Pharmaceuticals Alpha and Beta module to complement your research on InMed Pharmaceuticals. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
InMed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.